Enanta Pharmaceuticals Inc (ENTA) financials
Enanta Pharmaceuticals revenue and earnings by year
Enanta Pharmaceuticals's revenue was $65.3 million in the fiscal year to September 30, 2025, down 3.4% from the year before. Net income was -$81.9 million, -125.4% of revenue. Since the fiscal year to September 30, 2016, revenue has shrunk 3.3% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65 | 68 | 79 | 86 | 97 | 122 | 205 | 207 | 103 | 88 |
| Revenue growth | -3.4% | -14.6% | -8.1% | -11.2% | -20.7% | -40.3% | -0.7% | 101.0% | 16.5% | — |
| Operating income | -85 | -122 | -137 | -124 | -110 | -42 | 37 | 88 | 25 | 31 |
| Operating margin | -130.7% | -179.9% | -173.2% | -143.7% | -112.9% | -34.0% | 17.9% | 42.7% | 23.9% | 34.9% |
| Net income | -82 | -116 | -134 | -122 | -79 | -36 | 46 | 72 | 18 | 22 |
| Net margin | -125.4% | -171.6% | -169.0% | -141.3% | -81.4% | -29.5% | 22.6% | 34.8% | 17.2% | 24.5% |
| Diluted EPS | -$3.84 | -$5.48 | -$6.38 | -$5.91 | -$3.92 | -$1.82 | $2.22 | $3.47 | $0.88 | $1.13 |
| Free cash flow | -32 | -97 | -112 | -87 | -71 | 6 | 66 | 26 | 50 | 31 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open ENTA in Markets.
See also: ENTA valuation and P/E history · ENTA returns
No forecast, no recommendation. This page describes Enanta Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.